Is lactic acid an early signifier of mesothelioma?
A joint US/Chile research team is investigating how cellular lactic acid levels could assist early diagnosis of mesothelioma
, potentially saving thousands of lives.
Researchers at Chile's Centro de Estudios Cientificos are hoping to develop a non-invasive diagnostic tool for cancer which identifies lactic acid volumes in individual cells by way of a molecular sensor
The research could have important implications for the battle against mesothelioma; an aggressive, asbestos-related cancer
which attacks the lung linings and of which positive diagnoses often come too late
to prevent spread beyond the reach of surgery.
The Chilean team, in co-operation with Wolf Frommer of California's Carnegie Institution for Science, claims the new tool will detect lactic acid non-invasively in single cells faster than any other measurement procedure
The potential benefits of the new method lie in the fact that cancer cells produce lactic acid 3 to 5 times quicker
than non-tumour cells. "The high rate of lactate production in the cancer cell is the hallmark of cancer metabolism," Prof Frommer said in a press statement.
He added that the outcome will aid clinicians' comprehension of the subtleties of cancer and the creation of new ways to combat it.
Prof Frommer's US research base has spearheaded the development of Forster Resonance Energy Transfer (FRET)
sensors, which use a modest colour change to gauge the flow of sugars in individual cells.
Researchers say the sensor has quantified unusually low levels of lactic acid and can deliver an "unprecedented" spectrum of sensitivity and detection
The research team's leader, Felipe Barros, said that by allowing measurement of individual cell metabolisms, the tool provides scientists with "a new window" for grasping how cancers such as mesothelioma work
"Standard methods to measure lactate are based on reactions among enzymes, which require a large number of cells in complex cell mixtures," Prof Barros said. "That makes it difficult or even impossible
to see how different types of cells are acting when cancerous."
Emma Costin, Head of Industrial Disease at Simpson Millar comments: "Any new tools that will help in the early diagnosis of mesothelioma are to be welcomed. All too often this dreadful disease is diagnosed in the last stages of the illness
, when the patient is too frail to undergo surgery or chemotherapy. Those who represent victims and their families will watch the development of this research with great interest."